lung cancer
Conditions
Interventions
erythrocyte-derived microparticles encapsulated methotrexate :erythrocyte-derived microparticles encapsulated methotrexate
Sponsors
Xiangyang Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed as lung cancer; 2. Stable vital sign with Karnofsky index (KPS - Karnofsky Performance Status) more than 70; 3. Aged 18-75 years old; 4. Normal bone marrow hematopoietic function, no bleeding, blood routine: HGB >=90g/L, WBC >4.0*10^9/L; (NEU>=1.5*10^9/L), PLT>=100*10^9/L; 5. Liver function: total bilirubin <=1.5ULN; AST?ALT<=2.5ULN; Alkaline phosphatase<=1.5ULN; 6. BUN within 1.5 time upper limit of normal; Creatinine clearance rate more than 50mL/min; 7. Normal ECG, normal blood sugar levels; no other severe cardiopulmonary diseases 8. Agreed to participate in the study and sign an informed consent; 9. Without other severe comorbidities.
Exclusion criteria
Exclusion criteria: 1. Without pathological diagnosis; 2. Pregnant or lactating patients; 3. Allergy to multiple drugs; 4. With other severe comorbidities or psychological diseases; 5. Severe infection; 6. HIV positive; Treponema pallidum antibody positive;HCV positive;HBV positive; 7. Cognitive dysfunction; 8. Participation in other clinical trials within the recent four weeks; 9. Not available to participate in this clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| KPS;PS;Tumor volume; | — |
Countries
China
Contacts
Public ContactTeinan Yi
Xiangyang Central Hospital
Outcome results
None listed